OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 23, 2016 -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, and Richard Altieri, Chief Financial Officer, will present at the Cowen and Company 36th Annual Health Care Conference on Tuesday, March 8, 2016, at 9:20 a.m. EST at the Boston Marriott Copley Place in Boston, MA.
A live webcast of the presentation will be available online from the investor relations page of the Company's corporate website at www.oxfordimmunotec.com. A webcast replay will be available approximately 24 hours after the live presentation and will be archived on the website for approximately 60 days.
About Oxford Immunotec
Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions. The Company's first product is the T-SPOT®.TB test, which is used to test for tuberculosis infection. The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The T-SPOT.CMV test and the T-SPOT.PRT test are the Company's second and third products and part of a series of products intended for the transplantation market. In addition to these three products, the Company has an additional six active development programs, each of which leverages our T cell, B cell and innate immune measuring technology. The Company is headquartered near Oxford, U.K. and in Marlborough, Mass. Additional information can be found at www.oxfordimmunotec.com.
T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.
CONTACTS:
For Media Inquiries:
Caroline Crawley
Oxford Immunotec
Tel: +44 1235 442796
[email protected]
For Investor Inquiries:
Rick Altieri
Chief Financial Officer
Oxford Immunotec
Tel: +1 (508) 573-9953
[email protected]
Mark Klausner
Westwicke Partners
Tel: +1 (443) 213-0500
[email protected]


SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post
Nissan Halts Electric Qashqai Development Amid EV Market Challenges
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan
Alphabet Replaces Verizon in Dow Jones Industrial Average
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive
Doncasters Raises $919 Million in NYSE IPO as Aerospace Growth Accelerates 



